tiprankstipranks
Trending News
More News >
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
US Market

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Compare
442 Followers
See the Price Targets and Ratings of:

FHTX Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Foghorn
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FHTX Stock 12 Month Forecast

Average Price Target

$11.40
▲(97.23% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Foghorn Therapeutics in the last 3 months. The average price target is $11.40 with a high forecast of $14.00 and a low forecast of $10.00. The average price target represents a 97.23% change from the last price of $5.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.76,6.3938461538461535,7.027692307692307,7.661538461538461,8.295384615384615,8.929230769230768,9.563076923076924,10.196923076923078,10.830769230769231,11.464615384615385,12.098461538461539,12.732307692307693,13.366153846153846,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.76,6.193846153846153,6.627692307692308,7.061538461538461,7.495384615384616,7.929230769230769,8.363076923076923,8.796923076923077,9.23076923076923,9.664615384615384,10.098461538461539,10.532307692307693,10.966153846153846,{"y":11.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.76,6.086153846153846,6.412307692307692,6.7384615384615385,7.064615384615385,7.390769230769231,7.716923076923077,8.043076923076923,8.36923076923077,8.695384615384615,9.021538461538462,9.347692307692308,9.673846153846153,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.00Average Price Target$11.40Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on FHTX
Stifel Nicolaus
Stifel Nicolaus
$12
Buy
107.61%
Upside
Reiterated
02/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Qiagen (NYSE: QGEN) and Foghorn Therapeutics (NASDAQ: FHTX)
BTIG
$11
Buy
90.31%
Upside
Reiterated
01/13/26
Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)
Wedbush
$10
Buy
73.01%
Upside
Reiterated
01/12/26
Reiterate OUTPERFORM and our $10 PT.
Evercore ISI Analyst forecast on FHTX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$14
Buy
142.21%
Upside
Reiterated
12/17/25
Evercore ISI Sticks to Their Buy Rating for Foghorn Therapeutics (FHTX)
B. Riley Securities Analyst forecast on FHTX
B. Riley Securities
B. Riley Securities
$10
Buy
73.01%
Upside
Reiterated
12/17/25
Analysts' Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON)
H.C. Wainwright Analyst forecast on FHTX
H.C. Wainwright
H.C. Wainwright
$13
Buy
124.91%
Upside
Reiterated
11/17/25
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
Guggenheim Analyst forecast on FHTX
Guggenheim
Guggenheim
$12
Buy
107.61%
Upside
Initiated
11/07/25
Foghorn Therapeutics initiated with a Buy at GuggenheimFoghorn Therapeutics initiated with a Buy at Guggenheim
TD Cowen Analyst forecast on FHTX
TD Cowen
TD Cowen
Buy
Reiterated
11/05/25
Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
Citizens JMP Analyst forecast on FHTX
Citizens JMP
Citizens JMP
$9
Buy
55.71%
Upside
Reiterated
10/31/25
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)
Morgan Stanley Analyst forecast on FHTX
Morgan Stanley
Morgan Stanley
$4
Hold
-30.80%
Downside
Reiterated
06/12/25
Morgan Stanley Reaffirms Their Hold Rating on Foghorn Therapeutics (FHTX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on FHTX
Stifel Nicolaus
Stifel Nicolaus
$12
Buy
107.61%
Upside
Reiterated
02/18/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Qiagen (NYSE: QGEN) and Foghorn Therapeutics (NASDAQ: FHTX)
BTIG
$11
Buy
90.31%
Upside
Reiterated
01/13/26
Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)
Wedbush
$10
Buy
73.01%
Upside
Reiterated
01/12/26
Reiterate OUTPERFORM and our $10 PT.
Evercore ISI Analyst forecast on FHTX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$14
Buy
142.21%
Upside
Reiterated
12/17/25
Evercore ISI Sticks to Their Buy Rating for Foghorn Therapeutics (FHTX)
B. Riley Securities Analyst forecast on FHTX
B. Riley Securities
B. Riley Securities
$10
Buy
73.01%
Upside
Reiterated
12/17/25
Analysts' Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON)
H.C. Wainwright Analyst forecast on FHTX
H.C. Wainwright
H.C. Wainwright
$13
Buy
124.91%
Upside
Reiterated
11/17/25
Strategic Drug Development and Scientific Rigor Drive Buy Rating for Foghorn Therapeutics
Guggenheim Analyst forecast on FHTX
Guggenheim
Guggenheim
$12
Buy
107.61%
Upside
Initiated
11/07/25
Foghorn Therapeutics initiated with a Buy at GuggenheimFoghorn Therapeutics initiated with a Buy at Guggenheim
TD Cowen Analyst forecast on FHTX
TD Cowen
TD Cowen
Buy
Reiterated
11/05/25
Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
Citizens JMP Analyst forecast on FHTX
Citizens JMP
Citizens JMP
$9
Buy
55.71%
Upside
Reiterated
10/31/25
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)
Morgan Stanley Analyst forecast on FHTX
Morgan Stanley
Morgan Stanley
$4
Hold
-30.80%
Downside
Reiterated
06/12/25
Morgan Stanley Reaffirms Their Hold Rating on Foghorn Therapeutics (FHTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Foghorn Therapeutics

3 Months
xxx
Success Rate
7/12 ratings generated profit
58%
Average Return
+16.65%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +16.65% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
7/13 ratings generated profit
54%
Average Return
+7.80%
a rating ―
Copying Yaron Werber's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +7.80% per trade.
2 Years
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+2.77%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +2.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FHTX Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
7
10
11
10
6
Buy
2
2
1
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
12
12
10
6
In the current month, FHTX has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. FHTX average Analyst price target in the past 3 months is 11.40.
Each month's total comprises the sum of three months' worth of ratings.

FHTX Financial Forecast

FHTX Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

FHTX Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

FHTX Stock Forecast FAQ

What is FHTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Foghorn Therapeutics’s 12-month average price target is 11.40.
    What is FHTX’s upside potential, based on the analysts’ average price target?
    Foghorn Therapeutics has 97.23% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FHTX a Buy, Sell or Hold?
          Foghorn Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Foghorn Therapeutics’s price target?
            The average price target for Foghorn Therapeutics is 11.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.00 ,the lowest forecast is $10.00. The average price target represents 97.23% Increase from the current price of $5.78.
              What do analysts say about Foghorn Therapeutics?
              Foghorn Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of FHTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.